Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AstraZeneca Trial Patient Dies

<< Previous

Bullboard Posts

Next >>

Comment by samrakon Oct 21, 2020 4:47pm

157 Views

Post# 31759017

RE:RE:RE:AstraZeneca Trial Patient Dies

Keep in mind that the death might have had nothing to do with the trial. HeartAttacks, strokes, aneurysms can also kill very quickly and occasionally at younger ages. In a large trial there is certainly a reasonable likelihood of unrelated fatalities.

<< Previous

Bullboard Posts

Next >>

Nextech CEO provides company update on Amazon deal and more